A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation (DOME)
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Durvalumab (Primary) ; Oleclumab (Primary)
- Indications Adenocarcinoma; Head and neck cancer; Non-small cell lung cancer; Pancreatic cancer; Pancreatic ductal carcinoma; Squamous cell cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Acronyms DOME
Most Recent Events
- 13 Nov 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 12 Aug 2020 Planned End Date changed from 2 Mar 2022 to 1 Jan 2023.
- 12 Aug 2020 Planned primary completion date changed from 2 Mar 2022 to 1 Jan 2023.